[{"id":"089a9873-0dbf-4d04-a926-ae092495901f","acronym":"ComboMATCH","url":"https://clinicaltrials.gov/study/NCT05554380","created_at":"2022-09-26T14:56:10.419Z","updated_at":"2025-02-25T12:38:22.753Z","phase":"Phase 2","brief_title":"Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554380 - ComboMATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT2","pipe":" | ","alterations":" AKT1 mutation","tags":["AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ipatasertib (RG7440)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-24"},{"id":"7fd8451e-e40a-4b5b-98c2-c1a67ba94776","acronym":"","url":"https://clinicaltrials.gov/study/NCT04192981","created_at":"2021-01-18T20:26:03.024Z","updated_at":"2024-07-02T16:35:09.028Z","phase":"Phase 1","brief_title":"GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases","source_id_and_acronym":"NCT04192981","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3CG • PIK3CD • PIK3CB • INPP4B • AKT2 • INPP5D • PIK3C3 • PIK3R2 • PIK3R3","pipe":"","alterations":" ","tags":["PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3CG • PIK3CD • PIK3CB • INPP4B • AKT2 • INPP5D • PIK3C3 • PIK3R2 • PIK3R3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paxalisib (GDC-0084)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-17"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"156d54c5-8d8f-476f-89e1-cf5c28672101","acronym":"","url":"https://clinicaltrials.gov/study/NCT05098327","created_at":"2021-10-28T17:56:21.946Z","updated_at":"2024-07-02T16:35:39.988Z","phase":"Phase 3","brief_title":"Pioglitazone and Insulin Resistance in ADT","source_id_and_acronym":"NCT05098327","lead_sponsor":"State University of New York at Buffalo","biomarkers":" AKT2 • IRS1 • TLR4 • MAPK8 • SOCS3","pipe":"","alterations":" ","tags":["AKT2 • IRS1 • TLR4 • MAPK8 • SOCS3"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-08-15"},{"id":"0b31801d-bfeb-43b6-a0a2-863055f3325d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03310541","created_at":"2021-01-19T14:57:57.429Z","updated_at":"2024-07-02T16:35:48.874Z","phase":"Phase 1","brief_title":"AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations","source_id_and_acronym":"NCT03310541","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" AKT2","pipe":" | ","alterations":" AKT3 mutation","tags":["AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • Truqap (capivasertib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/11/2017","start_date":" 10/11/2017","primary_txt":" Primary completion: 05/03/2023","primary_completion_date":" 05/03/2023","study_txt":" Completion: 05/03/2023","study_completion_date":" 05/03/2023","last_update_posted":"2023-05-05"},{"id":"cba504e9-1b20-4258-b52e-a18251022778","acronym":"IceCAP","url":"https://clinicaltrials.gov/study/NCT03673787","created_at":"2021-01-18T18:01:13.221Z","updated_at":"2024-07-02T16:36:13.368Z","phase":"Phase 1/2","brief_title":"A Trial of Ipatasertib in Combination With Atezolizumab","source_id_and_acronym":"NCT03673787 - IceCAP","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" PIK3CA • PTEN • AKT2","pipe":" | ","alterations":" PIK3CA mutation • AKT1 mutation","tags":["PIK3CA • PTEN • AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • ipatasertib (RG7440)"],"overall_status":"Recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2022-04-08"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"},{"id":"67594d86-d6cf-4b01-aefe-6548477c2d62","acronym":"EMR100018-001","url":"https://clinicaltrials.gov/study/NCT01971515","created_at":"2021-01-18T08:58:11.943Z","updated_at":"2024-07-02T16:37:06.726Z","phase":"Phase 1","brief_title":"First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT01971515 - EMR100018-001","lead_sponsor":"EMD Serono","biomarkers":" HER-2 • ER • PIK3CA • PGR • PTEN • AKT1 • mTOR • TSC2 • TSC1 • AKT2","pipe":" | ","alterations":" HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PIK3CA • PGR • PTEN • AKT1 • mTOR • TSC2 • TSC1 • AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • rupitasertib (DIACC3010)"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 12/13/2013","start_date":" 12/13/2013","primary_txt":" Primary completion: 08/09/2018","primary_completion_date":" 08/09/2018","study_txt":" Completion: 08/09/2018","study_completion_date":" 08/09/2018","last_update_posted":"2018-09-19"},{"id":"8fd9e0a5-26dd-43f5-b8b9-9671467c4e06","acronym":"","url":"https://clinicaltrials.gov/study/NCT00380029","created_at":"2021-01-24T05:54:01.526Z","updated_at":"2025-02-25T15:24:41.786Z","phase":"Phase 2","brief_title":"Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT00380029","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" AKT2","pipe":" | ","alterations":" AKT2 expression","tags":["AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 08/01/2010","primary_completion_date":" 08/01/2010","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2017-07-19"}]